Literature DB >> 24885795

Cucurbitacin-E inhibits multiple cancer cells proliferation through attenuation of Wnt/β-catenin signaling.

Hui Feng1, Li Zang, Zhen-Xia Zhao, Quan-Cheng Kan.   

Abstract

Recent studies suggest that the use of cucurbitacins could inhibit cancer cell progression. In the current study, the authors analyzed the effect of cucurbitacin-E (CuE) in cancer cells using A549, Hep3B, and SW480 cells. The authors found that CuE inhibited cell proliferation and modulated the expression of cell cycle regulators in these cells. Moreover, the authors found that CuE inhibited Wnt/β-catenin signaling activation through upregulation of tumor suppressor Menin. Indeed, ablation of Menin using small interfering RNA (siRNA) oligos attenuated the antiproliferative roles of CuE. Taken together, the results of this study provide a novel mechanism that may contribute to the antineoplastic effects of CuE in cancer cells.

Entities:  

Keywords:  Menin; Wnt/β-catenin signaling; cell proliferation; cucurbitacin-E

Mesh:

Substances:

Year:  2014        PMID: 24885795     DOI: 10.1089/cbr.2014.1614

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  8 in total

1.  Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.

Authors:  Izabella Thaís Silva; Fabiana Cristina Geller; Lara Persich; Sabine Eva Dudek; Karen Luise Lang; Miguel Soriano Balparda Caro; Fernando Javier Durán; Eloir Paulo Schenkel; Stephan Ludwig; Cláudia Maria Oliveira Simões
Journal:  Invest New Drugs       Date:  2016-01-16       Impact factor: 3.850

2.  Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance.

Authors:  Longlong Xie; Feng Shi; Yueshuo Li; We Li; Xinfang Yu; Lin Zhao; Min Zhou; Jianmin Hu; Xiangjian Luo; Min Tang; Jia Fan; Jian Zhou; Qiang Gao; Weizhong Wu; Xin Zhang; Weihua Liao; Ann M Bode; Ya Cao
Journal:  Signal Transduct Target Ther       Date:  2020-05-20

Review 3.  Use of cucurbitacins for lung cancer research and therapy.

Authors:  Min Liu; Qijia Yan; Bi Peng; Yuan Cai; Shuangshuang Zeng; Zhijie Xu; Yuanliang Yan; Zhicheng Gong
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-06       Impact factor: 3.333

4.  Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway.

Authors:  Munazza Murtaza; Gulnaz Khan; Meha Fatima Aftab; Shabbir Khan Afridi; Safina Ghaffar; Ayaz Ahmed; Rahman M Hafizur; Rizwana Sanaullah Waraich
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

5.  Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model.

Authors:  Ping-Chih Hsu; Bo Tian; Yi-Lin Yang; Yu-Cheng Wang; Shu Liu; Anatoly Urisman; Cheng-Ta Yang; Zhidong Xu; David M Jablons; Liang You
Journal:  Oncol Rep       Date:  2019-06-20       Impact factor: 3.906

6.  The effects of cucurbitacin E on GADD45β-trigger G2/M arrest and JNK-independent pathway in brain cancer cells.

Authors:  An-Chin Cheng; Yi-Chiang Hsu; Chiang-Chin Tsai
Journal:  J Cell Mol Med       Date:  2019-03-25       Impact factor: 5.310

7.  Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation.

Authors:  Wenzhang Si; Jia Lyu; Zhengchuang Liu; Chunyang Wang; Jingjing Huang; Liping Jiang; Tonghui Ma
Journal:  J Cancer       Date:  2019-10-06       Impact factor: 4.207

8.  An updated review of Cucurbitacins and their biological and pharmacological activities.

Authors:  Sun Ok Chung; Yong Joo Kim; Sang Un Park
Journal:  EXCLI J       Date:  2015-05-05       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.